Skip to main content

This is a preprint.

It has not yet been peer reviewed by a journal.

The National Library of Medicine is running a pilot to include preprints that result from research funded by NIH in PMC and PubMed.

bioRxiv logoLink to bioRxiv
[Preprint]. 2023 Jul 3:2023.07.02.547361. [Version 1] doi: 10.1101/2023.07.02.547361

Glycoprotein VI is Critical for the Detection and Progression of Abdominal Aortic Aneurysms

Tyler W Benson, Mindy M Pike, Anthony Spuzzillo, Sarah M Hicks, Michael Pham, Doran S Mix, Seth I Brunner, Caris Wadding-Lee, Kelsey A Conrad, Hannah M Russell, Courtney Jennings, Taylor M Coughlin, Anu Aggarwal, Sean Lyden, Kevin Mani, Martin Björck, Anders Wanhainen, Rohan Bhandari, Loren Lipworth-Elliot, Cassianne Robinson-Cohen, Francis J Caputo, Sharon Shim, Todd L Edwards, Michael Tranter, Elizabeth E Gardiner, Nigel Mackman, Scott J Cameron, A Phillip Owens
PMCID: PMC10349971  PMID: 37461445

ABSTRACT

A common feature in patients with abdominal aortic aneurysms (AAA) is the formation of a nonocclusive intraluminal thrombus (ILT) in regions of aortic dilation. Platelets are known to maintain hemostasis and propagate thrombosis through several redundant activation mechanisms, yet the role of platelet activation in the pathogenesis of AAA associated ILT is still poorly understood. Thus, we sought to investigate how platelet activation impacts the pathogenesis of AAA. Using RNA-sequencing, we identify that the platelet-associated transcripts are significantly enriched in the ILT compared to the adjacent aneurysm wall and healthy control aortas. We found that the platelet specific receptor glycoprotein VI (GPVI) is among the top enriched genes in AAA ILT and is increased on the platelet surface of AAA patients. Examination of a specific indicator of platelet activity, soluble GPVI (sGPVI), in two independent AAA patient cohorts is highly predictive of a AAA diagnosis and associates more strongly with aneurysm growth rate when compared to D-dimer in humans. Finally, intervention with the anti-GPVI antibody (J) in mice with established aneurysms blunted the progression of AAA in two independent mouse models. In conclusion, we show that levels of sGPVI in humans can predict a diagnosis of AAA and AAA growth rate, which may be critical in the identification of high-risk patients. We also identify GPVI as a novel platelet-specific AAA therapeutic target, with minimal risk of adverse bleeding complications, where none currently exist.

KEY POINTS

  • Soluble glycoprotein VI, which is a platelet-derived blood biomarker, predicts a diagnosis of AAA, with high sensitivity and specificity in distinguishing patients with fast from slow-growing AAA.

  • Blockade of glycoprotein VI in mice with established aneurysms reduces AAA progression and mortality, indicating therapeutic potential.

Full Text Availability

The license terms selected by the author(s) for this preprint version do not permit archiving in PMC. The full text is available from the preprint server.


Articles from bioRxiv are provided here courtesy of Cold Spring Harbor Laboratory Preprints

RESOURCES